Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

BMC Infectious Diseases

Volumn 5, Issue , 2005, Pages

  Falagas, Matthew E ^a,b,c   Bliziotis, Ioannis A ^c   Kasiakou, Sofia K ^c   Samonis, George ^d   Athanassopoulou, Panayiota ^c   Michalopoulos, Argyris ^e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Alfa HealthCare   (Greece)

^d UNIVERSITY OF CRETE   (Greece)

^e HENRY DUNANT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; ISEPAMICIN; MEROPENEM; MONOBACTAM; NETILMICIN; OFLOXACIN; PEFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; DISEASE SEVERITY; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 25444462811     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-5-24     Document Type: Article

References (27)

1. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, Barrero-Almodovar AE, Garcia-Garmendia JL, Bernabeu-Wittell M, Gallego-Lara SL, Madrazo-Osuna J: Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36:1111-1118.
2. Michalopoulos AS, Tsiodras S, Rellos K, Mentzelopoulos S, Falagas ME: Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121.
3. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, Luh KT: Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002, 8:827-832.
4. Kuo LC, Yu CJ, Lee LN, Wang JL, Wang HC, Hsueh PR, Yang PC: Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc 2003, 102:601-606.
5. Denton M, Kerr K, Mooney L, Keer V, Rajgopal A, Brownlee K, Arundel P, Conway S: Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 2002, 34:257-261.
6. Tamm M, Eich C, Frei R, Gilgen S, Breitenbucher A, Mordasini C: [Inhaled colistin in cystic fibrosis]. Schweiz Med Wochenschr 2000, 130:1366-1372.
7. Catchpole CR, Andrews JM, Brenwald N, Wise R: A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997, 39:255-260.
8. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J: Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000, 31:101-106.
9. Giamarellos-Bourboulis EJ, Sambatakou H, Galani I, Giamarellou H: In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J Chemother 2003, 15:235-238.
10. Pitt TL, Sparrow M, Warner M, Stefanidou M: Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794-796.
11. Spence RP, Towner KJ, Henwood CJ, James D, Woodford N, Livermore DM: Population structure and antibiotic resistance of Acinetobacter DNA group 2 and 13TU isolates from hospitals in the UK. J Med Microbiol 2002, 51:1107-1112.
12. Valero E, Sevillano D, Calvo A, Garcia R, Leturia A, Gomez-Lus ML: [Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii]. Rev Esp Quimioter 2001, 14:358-363.
13. Gaynes RP, Horan TC: Surveillance of nosocomial infections. Appendix A: CDC definitions of nosocomial infections. In Hospital epidemiology and infection control Edited by: Mayhall CG. Baltimore: Williams & Wilkins; 1996:1-14.
14. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disc susceptibility tests. Approved standard M2-A2 S2. Waynee, PA NCCLS 1981.
15. Rynn C, Wootton M, Bowker KE, Alan HH, Reeves DS: In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999, 5:32-36.
16. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H: Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002, 44:259-263.
17. Gunderson BW, Ibrahim KH, Hovde LB, Fromm TL, Reed MD, Rotschafer JC: Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003, 47:905-909.
18. Ciofu O, Fussing V, Bagge N, Koch C, Hoiby N: Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother 2001, 48:391-396.
19. Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the managment of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005 in press.
20. Moore RA, Chan L, Hancock RE: Evidence for two distinct mechanisms of resistance to polymyxin B in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1984, 26:539-545.
21. Groisman EA, Kayser J, Soncini FC: Regulation of polymyxin resistance and adaptation to low-Mg2+ environments. J Bacteriol 1997, 179:7040-7045.
22. Nicas TI, Hancock RE: Outer membrane protein H1 of Pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980, 143:872-878.
23. Moore RA, Hancock RE: Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986, 30:923-926.
24. Gunn JS, Lim KB, Krueger J, Kim K, Guo L, Hackett M, Miller SI: PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 1998, 27:1171-1182.
25. Bengoechea JA, Skurnik M: Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia. Mol Microbiol 2000, 37:67-80.
26. Ito-Kagawa M, Koyama Y: Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiot (Tokyo) 1980, 33:1551-1555.
27. Gales AC, Reis AO, Jones RN: Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190.